Table 1.
Studies of various disease sites and outcomes with the use of BNCT. BNCT Phase I/II clinical trials have been carried out in a variety of disease sites, including recurrent glioblastoma, primary and recurrent head and neck cancer, meningioma, melanoma, hepatocellular carcinoma, and malignant mesothelioma.
| Glioblastoma Multiforme | |||
| Study | Number of Patients | Boron Carrier | Outcomes |
| Henriksson et al., 2008 | 30 | BPA-F | Median OS: 14.2 months Median time to progression: 5.8 months |
| Chanana et al., 1999 | 38 | BPA-F | Median OS: 13 months Median time to progression: 31.6 weeks |
| Miyatake et al., 2016 | 167 | BPA-F | Median survival: 9.6 months |
| Shiba et al., 2018 | 7 | Combination BPA with Bevacizumab | Median OS: 15.1 months Median time to progression: 5.4 months |
| Head and Neck | |||
| Study | Number of Patients | Boron Carrier | Outcomes |
| Kankaaranta et al., 2012 | 30 | BPA-F | Response rate: 76% Median PFS: 7.5 months 2 year OS: 30% |
| Head and Neck (Recurrent) | |||
| Study | Number of Patients | Boron Carrier | Outcomes |
| Suzuki et al., 2014 | 62 | BPA alone or BPA and BSH |
Median survival: 10.1 months Response rate: 58% 2 year OS: 24.2% |
| Koivunoro et al., 2019 | 79 | BPA-F | Complete response rate: 36% 2 year LRPFS 38% 2 year OS 21% |
| Wang et al., 2014, 2018, 2019 | 23 | BPA-F | 2 year locoregional control: 28% 2 year OS: 47% |
| Hirose et al., 2021 | Steboronine® | Objective response rate: 71% 2 year OS for recurrent SCC: 58% Median LRPFS: 11.5 months |
|
| Melanoma | |||
| Study | Number of Patients | Boron Carrier | Outcomes |
| Menendez et al., 2009 | 7 | BPA-F | Overall response rate: 69% Grade 3 toxicity rate: 30% |
| Meningioma | |||
| Study | Number of Patients | Boron Carrier | Outcomes |
| Takeuchi et al., 2018 | 31 | BPA-F | Median OS: 24.6 months |